PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22885662-0	2012	Inhibition of matrix metalloproteinase-2 by halofuginone is mediated by the Egr1 transcription factor.	halofuginone	44-56	matrix metallopeptidase 2	Homo sapiens	14-40	
26015407-6	2015	Moreover, halofuginone inhibits the TGF-beta/Smad3 cascade and the response of TGF-beta key targets involved in the metastases dissemination process such as MMP-2.	halofuginone	10-22	matrix metallopeptidase 2	Homo sapiens	157-162	
22885662-4	2012	We found a marked (50%) inhibition in MMP-2 gelatinolytic activity in human breast cancer MDA-MB-435 cells pretreated with as little as 50 ng/ml of halofuginone, a concentration that markedly inhibited their invasive and proliferative capacities.	halofuginone	148-160	matrix metallopeptidase 2	Homo sapiens	38-43	
22885662-7	2012	Altogether, our results identify the downstream elements (Egr-1, Nab-2, and MMP-2) by which halofuginone exerts its antitumoral effect, thereby advancing its potential therapeutic application as an anticancer drug.	halofuginone	92-104	matrix metallopeptidase 2	Homo sapiens	76-81	
21068672-1	2011	Using a novel blinded intrapatient vehicle control design, we conducted a phase II study of topically administered halofuginone, an angiogenesis inhibitor that inhibits collagen type-I and matrix metalloproteinases (MMPs), in patients with AIDS-related Kaposi sarcoma.	halofuginone	115-127	matrix metallopeptidase 2	Homo sapiens	216-220	
14506172-12	2003	Immunohistochemical studies revealed decreased collagen type I levels and vascular density in treated tumors and gelatinase assays of tumor extracts revealed a reduction of MMP-2 and MMP-9 activity in halofuginone-treated cells.	halofuginone	201-213	matrix metallopeptidase 2	Homo sapiens	173-178